A Kentucky woman suffering from chronic kidney disease claims that the manufacturers of Prilosec and Nexium are responsible for her pain and suffering. Earlier this month, she filed a proton pump inhibitor lawsuit accusing AstraZeneca and Proctor & Gamble of failing to warn consumers that long-term use of their products could harm the kidneys.
According to a complaint filed on January 9th in the U.S. District Court, Eastern District of Pennsylvania, Wanda Stafford was prescribed Nexium at various times between 2004 and 2009. Between 2009 and 2015, she was prescribed both Prilosec and Prilosec OTC on several occasions. Her lawsuit indicates that her chronic kidney disease was diagnosed in 2009. However, she only recently became aware that the proton pump inhibitors could have caused the disorder.
Stafford’s lawsuit cites a growing body of research that has linked long-term proton pump inhibitor use with an increased risk of chronic kidney disease and other renal injuries.
“Studies have shown the long term use of PPIs was independently associated with a 20% to 50% higher risk of CKD, after adjusting for several potential confounding variables, including demographics, socioeconomic status, clinical measurements, prevalent co-morbidities, and concomitant use of medications. In at least one study, the use of PPIs for any period of time, was shown to increase the risk of CKD by 10%,” the lawsuit states. “Currently, the Nexium, Prilosec and Prilosec OTC product labeling does not contain any warning regarding the increased risk of CKD.”
“Despite clear knowledge that Nexium causes a significantly increased risk of CKD and acute kidney injuries, Defendants continued to market and sell Nexium without warning consumers or healthcare providers of the significant risks of CKD and acute kidney injuries,” the complaint continues.
Stafford is just one of numerous plaintiffs now pursuing proton pump inhibitor lawsuits for kidney failure, chronic kidney disease, acute interstitial nephritis and acute kidney injury. Next week, the U.S. Judicial Panel on Multidistrict Litigation (JPML) will hear Oral Arguments on a Motion to Transfer all federally-filed claims of this nature to a single U.S. District Court for the purposes of coordinated pretrial proceedings. While plaintiffs contend that the creation of a multidistrict litigation for the federal proton pump inhibitor docket would promote judicial deficiency, AstraZeneca, Proctor & Gamble and other defendants are opposed to centralization.
Bernstein Liebhard LLP is representing plaintiffs in the growing proton pump inhibitor litigation. Individuals who were diagnosed with serious kidney complications following long-term use of Nexium, Prilosec or another drug in this class are urged to call (888) 994-8177 to obtain a free, no-obligation review of their potential case.